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Investigation of the potential therapeutic mechanisms of drug candidates is an essential step in the process of new drug discovery. 
With the rapid development of systems biology, recent network analyses of proteins, drugs, and diseases have enabled great pro-
gress in delineating the molecule mechanisms of drug candidates. However, most analyses perform a direct association between 
gene/protein and disease levels without considering the intermediate biological pathways regulated by the drugs. Given that a 
protein performs its biological roles through pathways, we propose using a novel pathway-pathway network analysis to investi-
gate the potential therapeutic functions of the drug candidates. Many studies have demonstrated that salvianolic acid B (Sal B) of 
Salvia miltiorrhiza is an effective therapy for cardiovascular diseases (CVD). Using molecular docking methods to identify direct 
interacting targets of Sal B, we collected all Sal B-regulated proteins with supporting experimental evidence in PubMed abstracts. 
FDA-approved CVD drugs and their corresponding targets were also collected. From a traditional drug-protein network analysis, 
we found that Sal B could affect ACE and REN of the renin-angiotensin-aldosterone system to relax vessels and alleviate hyper-
tension. Subsequent pathway-pathway network analysis was attempted to study the mechanisms of Sal B in treating CVD, and 
demonstrated that Sal B regulates immunity/inflammation, apoptosis, ion transport and basic metabolism processes in the treat-
ment of CVD. Regulating the immune/inflammation process may be the major mechanism of Sal B. We believe that pathway- 
pathway network analysis is a novel method for studying the therapeutic mechanisms of herbal ingredients. 
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Defining the mechanism by which candidate drugs act is an 
indispensable step in the process of drug discovery. Tradi-
tional discovery methods often produce relatively accurate 
outcomes but usually require huge expenditure of time and 
money. In recent years, network analyses based on pro-
tein-protein interactions, drug-drug association networks 
and disease-drug association networks have achieved good 
results in researching the mechanisms by which candidate 
drugs exert therapeutic effects in disease [1–5]. Network 
analyses based on protein-protein interactions mainly study 
topological characteristics of targets or proteins influenced 
by drugs in a given biological network, or the relative dis-
tance between disease-associated proteins, to deepen the 
understanding of the molecular mechanisms of drugs [1–3]. 
For example, Yue et al. [6] constructed a network consisting 
of all possible ganoderic acid D (GAD) targets, all of which 
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were supported by experimental evidence, then analyzed the 
relationships between these proteins and the cytotoxicity of 
GAD on the network. Other methods help us to understand 
the therapeutic mechanism of drugs by analyzing drug-drug 
association networks, which are constructed with drugs tar-
geting the same disease. This method predicts that drugs 
with the same therapeutic effect may also share a common 
therapeutic mechanism by targeting not only known drug 
targets, but also by interacting unexpectedly with a shared 
“cryptic” target(s) [4]. In addition, analyzing the associated 
network of genes/proteins, drugs or diseases based on the 
similarity of gene-expression profile signatures can predict 
possible influences of known drugs on other diseases, and 
facilitate a full understanding of the regulatory mechanisms 
employed by these drugs [5]. 
Although significant developments have been made in 
studying the therapeutic mechanisms of drugs using analyt-
ical methods to interrogate biological association networks, 
most analyses perform a direct association from the gene/ 
protein level to the disease level. However, there is a con-
siderable gap between single proteins and physiological or 
disease symptoms, which limits the degree to which these 
predictions can be translated to the whole organism. In vivo, 
a biologically active compound usually associates with 
many genes or proteins, each of which can be related to a 
variety of diseases, which can confuse efforts to define the 
predicted pharmacology of a bioactive compound. Proteins 
usually perform their physiological function by forming 
protein complexes or participating in biological signaling 
pathways [7]. Disease is often a much more complex physi-
ological phenomenon, its pathological processes generally 
being related to many abnormal biological pathways. To 
overcome this deficiency, pathway-pathway associated 
networks have been proposed that are composed of many 
biological pathways based on mutual links or crosstalk, and 
that can better reflect the complexity up- and down-stream 
of a given target within a network of human biological 
pathways. As biological pathway research advances, an in-
creasing number of reliable biological pathways with credible 
information regarding mutual crosstalk have been identified, 
which should greatly facilitate the construction of biological 
pathway-associated networks [8]. 
In general, Western drugs are designed to be mono- 
therapies (i.e. single active ingredient acting at a single tar-
get). In contrast, traditional Chinese medicine incorporates a 
variety of ingredients that can synergistically regulate vari-
ous related biological pathways through multiple targets. 
This synergy may contribute to the ultimate therapeutic ef-
fect [9–11]. Therefore, applying biological pathway-asso-    
ciated network analyses to the study of the molecular 
mechanisms of drug action seems suited to traditional Chi-
nese medicines. 
Many pharmacological studies have discovered that sal-
vianolic acid B (Sal B), a principal component of Salvia 
miltiorrhiza, is efficacious in curing cardiovascular disease 
(CVD) [12,13], a conclusion supported by US FDA phase II 
clinical trials. In addition, some researchers suggested that 
many cellular functions such as signal transmission are 
achieved by the mutual interaction of many biological mod-
ules, each with their own specific physiological function 
[14]. In this study, we used Sal B as an example to investi-
gate the relationship between functional modules and CVD 
based on a pathway-pathway association network, con-
structed using methods of target prediction, network assem-
bly and decomposition. 
1  Methods 
1.1  In silico salvianolic acid B target screening and 
collection of other regulated proteins 
In the field of molecular modeling, docking methods are 
used to predict the preferred orientation of one molecule in 
relation to a second when bound to each other in a stable 
complex. Molecular docking is used to evaluate the binding 
affinity of ligands and proteins according to space and en-
ergy matching, and is widely applied in molecular screening. 
Several excellent software programs have been developed, 
such as DOCK [15], AutoDock [16] and FleX [17]. 
INVDOCK [18] is the first reverse-docking software, which 
has been successfully used in potential target screening. Yue 
et al. [6] investigated the cellular toxicity of GAD based on 
21 potential targets identified by INVDOCK. In the current 
study, we collected all proteins with elaborate PDB struc-
ture which participated in 17 CVD-related GO [19] pro-
cesses (see Table 1, http://wiki.geneontology.org/index. 
php/Defining_CV-associated_gene_list). INVDOCK screen-
ing was then used to identify potential targets of Sal B. Ad-
ditionally, Sal B-regulated proteins were manually curated 
from the literature in Medline. To investigate the veracity of 
the relationship between the predicted targets and CVD, the 
distance between predicted targets and regulated proteins in 
the PPI (protein-protein interaction) network. The interacted 
protein-protein pairs were extracted from KEGG (Kyoto 
Encyclopedia of Genes and Genomes). 
1.2  Sal B target-drug association network 
The Anatomical Therapeutic Chemical (ATC) classification 
system is used for the classification of drugs. The drugs are 
divided into 14 main groups (1st level). The first level of the 
code indicates the anatomical main group and consists of 
one letter, for example, the ATC-code started with letter ‘C’ 
indicates that the agent is used for cardiovascular system 
disease. The curated CVD drugs whose first letter of ATC 
code is “C” and their corresponding targets (as verified by 
the FDA) were collected from DrugBank. The Sal B target- 
drug association network was then built based on the over-
lap targets of Sal B and CVD drugs. The Sal B target-drug 
association network was then built based on the overlap  
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Table 1  CVD related GO items 
GO ID GO term GO ID GO term 
GO:0007507 Heart development GO:0006979 Response to oxidative stress 
GO:0048738 Cardiac muscle development GO:0050817 Coagulation 
GO:0008015 Circulation GO:0006629 Lipid metabolism 
GO:0050878 Regulation of body fluids GO:0006936 Muscle contraction genes 
GO:0001944 Vasculature development GO:0048771 Tissue remodeling 
GO:0042060 Wound healing GO:0051145 Smooth muscle cell differentiation 
GO:0006979 Response to oxidative stress GO:0007517 Muscle development 
GO:0016055 Wnt receptor signaling pathway GO:0042692 Muscle cell differentiation 
GO:0048659 Smooth muscle cell proliferation  
 
targets of Sal B and CVD drugs. 
1.3  Pathway-pathway association network for Sal B 
To investigate the mechanism of Sal B in exerting a biolog-
ical effect at the pathway level, we removed the pathologi-
cal disease pathways in KEGG, including several basic 
pathways. A gene set enrichment analysis based on a hy-
per-geometric test was implemented toward the basic path-
ways. The pathway-pathway association network was con-
structed by creating targeted pathway interaction pairs for 
Sal B, according to the pathway-pathway interactions de-
fined in KEGG. In the network, each node represents a 
pathway, while each edge denotes a pathway-pathway in-
teraction. We then applied a simulated annealing algorithm 
to break up this network according to the minimization of 
modularity metric [20,21]. In addition to the regulated pro-
teins, the category information of pathways is considered in 
finding the primary biological process in each module. 
2  Results 
2.1  Statistical information on predicted and proven 
targets of Sal B 
In the Gene Ontology (GO) database, we gathered 1985 
CVD-associated human proteins based on 17 GO biological 
process terms related to CVD development. Fifty-eight Sal 
B targets were found by INVDOCK within 835 proteins 
whose 3D structural resolution was no more than 3Å. Ac-
cording to literature curated in PubMed, 11 experimentally 
proven protein targets regulated by Sal B in the treatment of 
CVD were collected and only a single regulated protein 
matched the predicted target set.  
It is well known that the targets predicted by docking are 
all direct targets. That is to say, only the proteins which 
physically bind with small molecule are identified as the 
potential targets. On the other hand, the regulated proteins 
curated from literatures only indicated that Sal B could in-
fluence the activity of the protein, whether their physically 
binding with Sal B is not required. The regulated proteins 
are not only the direct targets but also indirect targets or 
secondary targets. The regulated proteins may be close to 
the predicted targets. Therefore, we calculated the distances 
between the predicted targets and the regulated proteins in 
protein-protein interaction network. Among the 11 regulat-
ed proteins, 5 are 1 step from the predicted targets; 3 are 2 
steps from the predicted targets; 1 is 3 steps from the pre-
dicted targets; the last 1 protein is not in the network. About 
82% regulated proteins are located within two steps from 
their predicted targets. They might be the secondary targets 
affected by the direct targets. This may imply that Sal B 
might regulate CVD through these 58 targets. 
2.2  Analysis of target-drug association network 
In the DrugBank database, we found 160 FDA-approved 
small molecule drugs that are currently used to treat CVD 
and 193 corresponding targets. A Sal B drug-target associa-
tion network (Figure 1) was constructed based on the com-
mon targets between Sal B and the 160 drugs. In Figure 1, 9 
common targets and 23 CVD drugs are covered, with 2 
common targets overlapped between Sal B and Moexipril. 
Moexipril is considered to be an inhibitor of angioten-
sin-converting enzyme (ACE), which may regulate CVD 
similarly to hypertension or stroke by relaxing blood vessels 
to lower blood pressure. As a part of the renin-angiotensin- 
aldosterone system (RAAS), the ACE enzyme is responsi-
ble for the translation of angiotensin I to angiotensin II and 
inactivation of bradykinin [22]. ACE inhibitors that de-
crease the amount of angiotensin II and elevate bradykinin 
are often used to treat hypertension and coronary artery 
diseases. Sal B is related to moexipril through the vasocon-
striction effects associated with ACE, and ACE2 is classed 
as both a successful target (hit by an FDA-approved drug) 
and a research target (hit by a research drug). Given this 
status, it could be concluded that Sal B acts via a similar 
therapeutic mechanism to moexipril (i.e. anti-vasocon-     
striction through the inhibition of ACE) in treating CVD. 
Indeed, it has been shown that the aqueous extract of Salvia  
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Figure 1  The Sal B-target-drug association network. The square represents Sal B; circles are common targets between Sal B and drugs; diamonds are CVD 
therapeutic drugs. This figure was produced using Cytoscape software [24].  
miltiorrhiza, which includes Sal B, can inhibit ACE activity 
in rabbit lung tissue [23]. In addition, renin (REN), an im-
portant component of RAAS, is involved in the translation 
of angiotensinogen to angiotensin I and the development of 
vasoconstriction. The drugs remikiren and aliskiren exert 
anti-hypertensive effects by regulating REN. Given the re-
lationship of Sal B to these drugs, and its effect on REN, it 
could be suggested that Sal B regulates hypertension in a 
similar way, by interfering with REN. 
Figure 1 also shows several statin drugs such as simvas-
tatin, rosuvastatin and atorvastatin that treat CVD primarily 
by inhibiting the activation of HMG-CoA reductase. Con-
sidering that the common targets (TNF, CD40, NOS3) 
shared by Sal B and these drugs are not directly associated 
with the metabolism of cholesterol, it is unlikely that Sal B 
generates the same biological function as these statins. 
2.3  Analysis of pathway-pathway association network 
of Sal B 
The above analysis revealed potential parts of the biological 
function of Sal B, but this small number of common targets 
cannot provide comprehensive information for us to define 
comprehensively its therapeutic mechanism. Therefore, the 
pathway-pathway association network method was adopted 
to study the molecular mechanism of Sal B. First, mapping 
58 targets into the KEGG Pathway database, we retrieved 
86 basic pathways. The pathway-pathway association net-
work was constructed based on information regarding the 
connectivity of these 86 pathways, and the resultant net-
work contained 86 nodes and 190 edges. Eighty-two nodes 
are included in the largest component sub-network. There 
are also four isolated pathways in the network (Drug me-
tabolism—other enzymes; ABC transporters; Hematopoietic 
cell lineage; and Dorsoventral axis formation). Detailed 
information is listed in Figure S1. 
With the aim of minimizing the modularity metric, the 
simulated annealing algorithm was used to decompose the 
network. As shown in Figure 2, the network breaks down 
into six modules with a modular coefficient of 0.497 and Z 
score of 12.315, compared with an average modular coeffi-
cient of 0.008 for 10000 random cases with the same num-
ber of nodes and degree of distribution. According to the 
pathway classification information in the KEGG Pathway  
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Figure 2  Modularization of the pathway-pathway association network 
regulated by Sal B. Each circle represents a module in the pathway-pathway 
association network. The subdivision of each module reflects the relative 
representation of basic pathways within each of seven specified biological 
processes and an “Other” group. Edges are suggestive of a linkage between 
two modules and the thickness of edge reflects the number of linkages 
between them. 
database, 7 representative biological processes were as-
signed to the 82 basic pathways. These were: cell commu-
nication; cell growth and death; signal transduction; metab-
olism system; endocrine system; immune system; and ion 
transport system. Pathways not assigned into these 7 classes 
were denoted as “Other”. Detailed information is listed in 
Table S1. 
In Figure 2, it was clear that modules 1, 2, 3, 5 and 6 had 
relatively high network connectivity; module 1 was the 
most closely connected. In the modularized network, each 
module was composed of various basic pathways belonging 
to different biological processes, the ratio of which varied 
between modules. Modules 1 and 5 contained a larger 
number of biological processes than other modules, which 
implied that the two modules carried out relatively more 
complex biological functions. In module 1, 19 pathways 
were classed into 6 biological processes, with 10 pathways 
(52.63%) belonging to the “signal transduction” process and 
the remaining 9 pathways correspondingly categorized into 
“endocrine system”, “cell growth and death”, “cell commu-
nication”, “metabolism system” and “immune system” pro-
cesses. The close connection between module 1 and the 
other 5 modules indicates a potentially significant role of 
module 1 in maintaining normal biological function. Mod-
ule 1 primarily reflected basic cellular signal transduction 
processes regulated by Sal B. Furthermore, the node repre-
senting the MAPK signaling pathway in module 1 showed 
the largest network connectivity with 32 other nodes in the 
pathway-pathway association network and always took part 
in cellular proliferation, differentiation and apoptosis bio-
logical processes (see Figure S1). Abnormal signaling path-
ways have been implicated in CVD [25]; the MAPK path-
way has also been shown to play an important role in hy-
pertrophy, cardiac remodeling after myocardial infarction, 
atherosclerosis and vascular restenosis [26]. Sal B may exert 
therapeutic effects by regulating the “signal transduction” 
pathway module. 
In modules 2 and 5, “immune pathways” accounted for 
the largest proportion (0.75 and 0.43, respectively). With 
the largest degree of network connectivity in module 5, the 
“regulation of actin cytoskeleton” pathway had a significant 
role in several cellular processes such as migration, mor-
phogenesis and endocytosis, which are involved in cellular 
immunity and inflammation [27]. Modules 2, 5 and 3 were 
dominated by “immune/inflammation” processes. Some 
studies had indicated that cardiovascular disease was caused 
mainly by atherosclerosis related to macrophages, T cells 
and other cells of the immune response, together with cho-
lesterol infiltrating from the blood [28]. Although most 
pathways in module 3 belonged to the “immune system” 
process, some (such as the Toll-like receptor signaling 
pathway) also participated in cell apoptosis processes and 
were classified as “cell growth and death” pathways. The 
apoptosis pathway was the most connected node in module 
3, which may imply that this is the main function of the 
module. Apoptosis plays a key role in the pathogenesis of a 
variety of cardiovascular diseases to which the loss of ter-
minally differentiated cardiac myocytes is a contributory 
factor. Cardiac myocytes undergoing apoptosis have been 
identified in tissue samples from patients suffering from 
myocardial infarction, diabetic cardiomyopathy, and end- 
stage congestive heart failure. Evidence shows that inhibi-
tion of apoptosis was cardio-protective and could prevent 
the development of heart failure [29]. 
Module 6 mainly reflects ion transport processes. Among 
the nine pathways in module 6, five (55.6%) were associat-
ed with this function, of which the calcium-signaling path-
way possessed the largest network connectivity. The vascu-
lar smooth muscle contraction pathway in module 6 regu-
lated cellular Ca2+ concentration to stimulate vascular 
smooth muscle cell contraction, decreased vascular diame-
ter and ultimately modulated blood flow and pressure. Ab-
normality within this pathway was potentially pathogenic 
for some forms of CVD. 
Linking only with modules 1 and 2, module 4 had rela-
tively little network connectivity and performed a specialist 
biological function. The vast majority (92.59%) of path-
ways in this group were classified into the “metabolism” 
biological process that controls synthesis and metabolism of 
carbohydrates, lipids, proteins and nucleic acids. The gly-
colysis/gluconeogenesis pathway demonstrated the largest 
network connectivity in this module. In vivo, hormones and 
polysaccharides produced in the metabolism process medi-
ated cell recognition, cell communication and signal trans-
duction. Signal transduction pathways also regulated the 
normal metabolism process, so module 4 was closely con-
nected with module 1. From the characteristics of all six 
modules, it can be concluded that Sal B is involved in CVD 
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via actions on cellular apoptosis, metabolism, immunity/ 
inflammation and ion transport. 
Statistical analysis on the distribution of targets among 
the six modules showed that there were no enriched basic 
pathways in module 2, which contains fewer regulated pro-
teins and predicted targets (Figure 3). Module 4 contained 
no regulated proteins. Among the six modules, module 5 
contained the largest number of targets (22/50, or ~44%), 
regulated proteins (7/11, or ~63%), and the highest propor-
tion of target-enriched basic pathways. To regulate CVD, 
Sal B tended to affect module 5 (representing “immunity/ 
inflammation”) rather than modules 2 or 4. In addition, a 
hyper-geometric test was taken to evaluate enrichment of 
the predicted targets and regulated proteins in each module. 
The outcomes demonstrated that “targets” and “regulated 
proteins” were highly enriched in module 5 with P values of 
0.00039 and 0.00027, respectively. In module 4, the P value 
of “targets” was 0.04445 but there were no regulated proteins 
in the module so no statistical analysis was possible on this 
parameter. For all remaining modules, P values were >0.05, 
suggesting that there was no significant enrichment of either 
targets or regulated proteins in these modules. Therefore, in 
the following section, we focus on module 5 (“immunity/ 
inflammation” biological process) to further study the regu-
latory function of Sal B. 
2.4  The regulation of Sal B on immune/inflammation 
physiological process 
In module 5, Sal B regulation of CVD is dominated by ef-
fects on “immunity/inflammation” physiological function 
processes, which account for the largest number of targets 
and regulated proteins. It has been demonstrated that an 
increase in the migration and proliferation of macrophages, 
T lymphocytes, and smooth muscle cells underlies some of  
 
Figure 3  Statistical analysis of the number of targets, proven regulated 
proteins and target-enriched basic pathways in each module. X axis repre-
sents the six modules and Y axis represents the ratio of number of targets, 
regulated proteins and target-enriched pathways. 
the key cellular events in the atherogenic process, and this 
appears to be in response to the inflammatory activation of 
cells. This results in an increase in the secretion of cyto-
kines, chemoattractants, and growth regulatory molecules 
[30]. Therefore, the efficacy of Sal B in treating CVD may 
lie in its regulation of the 14 basic pathways in the “immunity/ 
inflammation” physiological module. We constructed an 
“immunity/inflammation” physiological network based on 
19 Sal B targets and 8 proven Sal B-regulated proteins in 
these 14 pathways and studied the therapeutic mechanism of 
Sal B in this network (Figure 4). 
In Figure 4, Sal B is shown to regulate 27 proteins, thus 
modulating immune activation, inflammatory actions, cell 
adherence and thrombus occurrence, all of which contribute 
to CVD development. It shows that Sal B may regulate 
immune activation by influencing KLKB1, GF, RIK, IR, 
CD40, PI3K, AKT, GSK3, MEK1/2 and CaN proteins. 
Some evidence has suggested that Sal B decreases inflam-
mation by inhibiting ICAM1, VCAM1 and NFκB [31]. In 
the coagulation cascade, Sal B possibly impacts AKT, 
PROC, REN and ACE to influence thrombus formation. Sal 
B also decreases the fibrinolytic and anticoagulant potential 
of human umbilical vein endothelial cells by up-regulating 
the expression of t-PA (PLAT) and TM (THBD), which 
form complexes with F2, decreasing the amount of F2 and 
leading to thrombus formation [32]. In addition, Sal B 
maybe impact PLAUR, INSR, PGFR1 and β-Caterin to 
regulate cell adhesion. 
3  Conclusions 
We retrieved 58 predicted Sal B targets using a docking 
method, and 11 proven Sal B-regulated proteins were col-
lected by manual curation in PubMed. From DrugBank, we 
defined 160 current FDA-approved CVD drugs and 193 
corresponding targets. From the Sal B drug-target associa-
tion network, we found that Sal B could impact ACE and 
REN in the renin-angiotensin-aldosterone system to relax 
blood vessels and regulate hypertension. Our pathway-pathway 
association network further demonstrated that Sal B can 
regulate immunity/inflammation, apoptosis, ion transport 
and basic metabolism physiological processes in the treat-
ment of CVD. Of these, regulation of the immune/inflam-     
mation process may be the major molecular mechanism of 
Sal B. 
Compared with protein-based analysis methods, we con-
structed a pathway-based network which was regulated by 
Sal B. This may increase our understanding of the regulato-
ry mechanisms modulated by Sal B in the treatment of CVD 
by giving full consideration to all aspects of the relationship 
between pathways and proteins. This represents an alterna-
tive to traditional methods such as transcriptomics. Our 
method analyzed molecular mechanisms from enrichment 
modules, not just proteins. This should decrease the number  
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Figure 4  “Immunity/inflammation” physiological network regulated by Sal B. Grey rounded rectangle nodes represent computed Sal B targets; black 
rounded rectangle nodes represent proven SalB-regulated proteins. The grey ellipse node (THBD) was present in both sets of proteins.  
of false positives and complement other methods. In sum-
mary, we hope that this new pathway-centric analysis method 
will advance our understanding of the mechanisms of action 
of bioactive herbal ingredients.  
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Figure S1  Pathway-pathway association network of Sal b. 
Table S1  Pathway information of Sal b 
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